Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1462 - 1470 |
| Number of pages | 9 |
| Journal | Gastroenterology |
| Volume | 149 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2015 |
Cite this
}
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. / Foster, Graham R; Pianko, Stephen; Brown, Ashley; Forton, Daniel M; Nahass, Ronald G; George, Jacob; Barnes, Eleanor; Brainard, Diana; Massetto, Benedetta; Lin, Ming; Han, Bin; McHutchison, John G; Subramanian, G Mani; Cooper, Curtis; Agarwal, Kosh.
In: Gastroenterology, Vol. 149, No. 6, 2015, p. 1462 - 1470.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection
AU - Foster, Graham R
AU - Pianko, Stephen
AU - Brown, Ashley
AU - Forton, Daniel M
AU - Nahass, Ronald G
AU - George, Jacob
AU - Barnes, Eleanor
AU - Brainard, Diana
AU - Massetto, Benedetta
AU - Lin, Ming
AU - Han, Bin
AU - McHutchison, John G
AU - Subramanian, G Mani
AU - Cooper, Curtis
AU - Agarwal, Kosh
PY - 2015
Y1 - 2015
N2 - Background and Aims We conducted an open-label, randomized, phase 3 trial to determine the efficacy and safety of sofosbuvir and ribavirin, with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis and hepatitis C virus (HCV) genotype 2 infection and treatment-naive or treatment-experienced patients with HCV genotype 3 infection. Methods The study was conducted at 80 sites in Europe, North America, Australia, and New Zealand Patients were randomly assigned (1:1:1) to groups given sofosbuvir and ribavirin for 16 weeks (n = 196); sofosbuvir and ribavirin for 24 weeks (n = 199); or sofosbuvir, peginterferon-alfa, and ribavirin for 12 weeks (n = 197). The primary end point was the percentage of patients with HCV RNA
AB - Background and Aims We conducted an open-label, randomized, phase 3 trial to determine the efficacy and safety of sofosbuvir and ribavirin, with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis and hepatitis C virus (HCV) genotype 2 infection and treatment-naive or treatment-experienced patients with HCV genotype 3 infection. Methods The study was conducted at 80 sites in Europe, North America, Australia, and New Zealand Patients were randomly assigned (1:1:1) to groups given sofosbuvir and ribavirin for 16 weeks (n = 196); sofosbuvir and ribavirin for 24 weeks (n = 199); or sofosbuvir, peginterferon-alfa, and ribavirin for 12 weeks (n = 197). The primary end point was the percentage of patients with HCV RNA
UR - http://www.gastrojournal.org/article/S0016-5085(15)01069-0/pdf
U2 - 10.1053/j.gastro.2015.07.043
DO - 10.1053/j.gastro.2015.07.043
M3 - Article
VL - 149
SP - 1462
EP - 1470
JO - Gastroenterology
JF - Gastroenterology
SN - 0016-5085
IS - 6
ER -